Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Changes in the amyloid editorial board members and in editor positions329
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement287
A second case of liraglutide-type localised amyloidosis125
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies116
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey81
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study32
Commentary to revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus25
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases25
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis23
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis22
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange21
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging20
A clinical and ECG based score to predict incident atrial fibrillation in cardiac amyloidosis: the Amy-Lyon AF score19
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains18
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study17
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy17
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus15
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis14
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay14
Clinical profile and outcome of AA amyloidosis associated kidney disease in India14
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival14
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Electric field-induced destabilization and surface modulation of Aβ42 fibrils in molecular simulations: theoretical implications for direct current stimulation in Alzheimer’s disease13
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody13
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study13
Clarifying the immunoglobulin light chain variable gene usage in Chinese patients with renal AL amyloidosis13
ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial Intelligence11
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice11
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China11
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage11
Frontline Dara-CyBorD for AL amyloidosis: high response rates and cytogenetic insights from a real-world cohort11
Brain MRI in patients with V30M hereditary transthyretin amyloidosis11
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis11
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)11
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures10
Refining prognostication in systemic AL amyloidosis: limited value of dFLC10
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis10
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?10
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark9
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation9
Correction9
Incidence of second primary malignancies in patients with AL amyloidosis and the impact of disease stage and therapies9
Accelerated apolipoprotein A-II senile amyloidosis in a plasminogen activator inhibitor-1 knock-out model9
AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review9
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant8
Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study8
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Incidence and predictors of sudden death in patients with cardiac amyloidosis7
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)7
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis7
Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis7
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy7
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation6
Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling6
Single-slide detection and typing of AL renal amyloidosis: combining mass spectrometry imaging and digital pathology6
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
In memoriam: Shukuro Araki, MD, PhD (1927–2025) pioneer of Japanese neurology and a global leader in familial amyloid polyneuropathy6
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis6
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis5
High rate of false negative 99m Tc-pyrophosphate scintigraphy scans in patients with Leu58His transthyretin amyloid cardiomyopathy5
Interactions between amyloid fibril proteins5
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis5
Amyloid myopathy in the internal oblique muscle of patients with wild-type transthyretin cardiac amyloidosis5
Limited diagnostic utility of systematic Congo red staining in bone marrow biopsies5
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant5
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up5
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy5
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy4
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis4
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis4
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee4
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?4
A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis4
A comparison of single versus combination mechanism treatment for transthyretin amyloid cardiomyopathy4
Hereditary transthyretin amyloidosis with cardiomyopathy and polyneuropathy associated with a novel pathogenic TTR Tyr105His (p.Tyr125His) mutation4
Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis4
Computed tomography-derived myocardial radiomics for detection of transthyretin amyloidosis in patients with severe aortic stenosis4
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis4
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis4
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study4
A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis4
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)3
The CATCH-ATTR study: CArpal Tunnel ligament amyloid—the Clue for early identification of Hereditary or wildtype systemic ATTR amyloidosis?3
Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis3
The role of cardiac imaging for diagnosis of cardiac amyloidosis: a systematic review and meta-analysis of test accuracy3
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects3
Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis3
Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis3
Binding of serum-derived amyloid-associated proteins to amyloid fibrils3
Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis3
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy3
Identification of calcitonin receptor-stimulating peptide 1-derived amyloid in a feline C-cell carcinoma3
Regarding the challenges of amyloidosis diagnosis and typing in Ukraine3
Optimized methods for efficient application of immunogold electron microscopy to amyloid fibrils typing3
Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?3
ATTR- and AFib amyloid - two different types of amyloid in the annular ligament of trigger finger3
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis2
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal2
XIX International Symposium on Amyloidosis Abstracts2
Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis2
Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis2
Right ventricular-pulmonary arterial coupling and outcomes in cardiac amyloidosis: systematic review and meta-analysis2
Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study2
No body fits in the test tube – the case of transthyretin2
Development and validation of the modified-comprehensive Kumamoto Score: a multi-organ assessment tool for hereditary transthyretin amyloidosis2
In memoriam: Lawreen Connors, Ph.D.2
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage2
Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients2
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and2
Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study2
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis2
Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions2
A report from the European Proteomics Amyloid Network (EPAN)2
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis2
0.78570795059204